Menopur (Menotrophin)

Menotrophin contains analogues of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After injection, FSH binds to receptors on ovarian granulosa cells, promoting follicle growth, while LH activates receptors on theca cells and mature follicles, leading to androgen production and final oocyte maturation, together facilitating ovulation.

The dose of Menopur is individualized. The prescribing clinician determines the amount and frequency based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted‑reproduction protocol being used.

Menopur is intended for use before conception to induce ovulation or stimulate follicle development. Its safety in established pregnancy or during breastfeeding has not been established, and it should not be used once pregnancy is confirmed without medical guidance.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Menopur provides a combination of FSH and LH activity in a single preparation, whereas some alternatives offer only FSH (e.g., follitropin alfa) and require a separate LH product if needed. This combined formulation can simplify dosing and reduce the number of injections for patients requiring both hormones.

Menopur should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Once reconstituted, it should be used within the time frame specified in the product labeling and kept under the same refrigerated conditions.

Menopur is administered by subcutaneous or intramuscular injection. The injection site should be rotated, and aseptic technique must be followed. Patients or healthcare providers are trained on proper reconstitution and injection methods to ensure accurate dosing.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and respiratory distress, and rare thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Prompt medical attention is required if these symptoms develop.

Menopur is contraindicated in patients with active ovarian cysts, uncontrolled thyroid disease, known hypersensitivity to menotrophin or any excipients, and in women who are already pregnant. It should also be used with caution in patients with a history of severe OHSS.